Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a little fat be the key to better dialysis access?

NCT ID NCT05136859

Disease control Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether leaving the fat around a vein intact during fistula surgery helps the fistula mature for dialysis. Patients with advanced kidney disease needing hemodialysis are randomly assigned to have that fat preserved or removed. The study tracks fistula maturation using ultrasound and checks blood and tissue samples for inflammation and fibrosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
preserving the perivascular fat of the target cephalic vein during arteriovenous fistula surgery
What this could lead to
If preserving the fat around the vein helps fistulas mature, it could reduce the need for repeat surgeries and improve dialysis access reliability.
What could go wrong
This is a small, early-stage trial, and the benefit may not be clear. Surgery risks like infection or bleeding remain, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age of 20 and older adult patients. 2. preoperatively clinical and ultrasound assessment of the arm vessels are visible for the creation of a native HDAVF that include：the augmented diameters of the veins is \> 2.0 mm and the diameter of the radial artery is\> 2.0 mm. Besides, there is no obvious stenosis of vessels in the forearm. Exclusion Criteria: 1. The patient refused to join the study 2. serious heart failure (Physicians identify insufficient cardiac output that may affect sacral blood flow development after surgery) 3. Unconsciousness 4. Bedridden for long time 5. systemic lupus erythematosus(SLE), or other known autoimmune diseases 6. The physician excludes the possibility of creating a wrist HDAVF before surgery 7. Surgeon preoperatively identifies vessel inadequacy for the creation of a wrist HDAVF 8. Choose a site other than the wrist for surgery 9. Unexpected complications happen during the surgery that prevent the completion of a wrist HDAVF

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arteriovenous fistula are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital arteriovenous fistula end stage renal failure Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arteriovenous fistula

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Taiwan University Hospital

    RECRUITING

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.